Biopharmaceutical company Avicanna Inc. announced the U.S. brand launch and commercialization of its proprietary and clinically backed cannabidiol (CBD) derma-cosmetics brand, Pura H&W, through its exclusive partnership with Red White and Bloom.
The U.S. market is the fourth nation in which Avicanna’s derma-cosmetic products branded as Pura H&W or Pura Earth have commercialized, including Colombia and Ecuador as well as Canada, where the products are available through medical and adult use channels.
Avicanna focuses on the development, manufacturing and commercialization of plant-derived cannabinoid-based pharmaceuticals. Pura Health & Wellness (Pura H&W) is Avicanna’s derma-cosmetic line which utilizes a combination of purified CBD and other synergistic botanical ingredients designed to naturally regulate and nourish the skin. The Pura H&W product line was developed by Avicanna and specific products have undergone clinical trials.
“This marks the first major market for the brand where the products will be accessible to consumers over the counter and nationwide,” said Avicanna CEO Aras Azadian. “We are optimistic about the launch of Pura in the United States, where we believe the clinically-backed and functional products will be highly differentiated and well supported by our strategic partners Red White and Bloom and their U.S. commercial infrastructure.”
The U.S. beauty industry continues to grow rapidly and innovative trends, such as the introduction of cannabinoid-based cosmetics, are expected to provide a strong market opportunity. The launch of the proprietary and clinically-backed CBD product line will leverage the growing use of online platforms for shopping including Pura H&W’s own e-commerce platform in addition to third party e-commerce channels, big-box retailers, and Red White and Bloom’s existing cannabis retail infrastructure across the United States.
“We are excited to launch the Pura brand in the U.S.,” said Red White & Bloom CEO Brad Rogers. “As the first clinically tested line in CBD cosmetics, the reaction from our stores and retail partners has been exciting and this is strategically aligned with our goal to be the most recognized and responsible multi state operator (MSO) in the market. We look forward to scaling the launch quickly in both our physical and digital channels.”
Three cosmetic clinical studies were completed on Avicanna’s formulations targeting cosmetic factors associated with aging, acne-prone skin and eczema-prone skin. The successfully completed studies involved 156 patients that were tested for safety and specific derma-cosmetic endpoints, including hydration and excess oil production.
All three studies achieved positive results in the endpoints with no adverse effects, making Pura H&W one of the only cannabinoid consumer lines with human safety and efficacy data. For more information on the clinical trials, visit the www.ClinicalTrials.gov registry.